69 results on '"Inzucchi, Silvio E."'
Search Results
2. Empagliflozin in patients with type 2 diabetes mellitus and chronic obstructive pulmonary disease
- Author
-
Anker, Stefan D., Sander, Leif-Erik, Fitchett, David H., Zinman, Bernard, Pernille Ofstad, Anne, Wanner, Christoph, Vedin, Ola, Lauer, Sabine, Verma, Subodh, Yaggi, Henry K., and Inzucchi, Silvio E.
- Published
- 2022
- Full Text
- View/download PDF
3. Heart Failure, Investigator-Reported Sleep Apnea and Dapagliflozin: A Patient-Level Pooled Meta-Analysis of DAPA-HF and DELIVER.
- Author
-
BUTT, JAWAD H., JERING, KAROLA, DE BOER, RUDOLF A., CLAGGETT, BRIAN L., DESAI, AKSHAY S., HERNANDEZ, ADRIAN F., INZUCCHI, SILVIO E., JHUND, PARDEEP S., KØBER, LARS, KOSIBOROD, MIKHAIL N., LAM, CAROLYN S.P., MARTINEZ, FELIPE A., PONIKOWSKI, PIOTR, SABATINE, MARC S., SHAH, SANJIV J., VADUGANATHAN, MUTHIAH, LANGKILDE, ANNA MARIA, BENGTSSON, OLOF, PETERSSON, MAGNUS, and SJÖSTRAND, MIKAELA
- Abstract
• Whether dapagliflozin is beneficial in patients with sleep apnea and heart failure, across the range of ejection fractions, is unknown. • In a pooled individual-level meta-analysis of DAPA-HF and DELIVER, investigator-reported sleep apnea was associated with a greater risk of worsening heart failure events. • Dapagliflozin, compared with placebo, reduced the risk of clinical outcomes and improved health-related quality of life in patients with and without sleep apnea. Sleep apnea is more common in patients with heart failure (HF) than in the general population, but little is known about its association with clinical outcomes in various HF phenotypes or how it might modify the effect of HF therapy. To examine the prevalence of sleep apnea, its association with outcomes and the effects of dapagliflozin in patients with HF with and without sleep apnea in a pooled analysis of 2 trials comparing dapagliflozin to placebo in HFrEF (DAPA-HF trial) and HFmrEF/HFpEF (DELIVER trial). A history of sleep apnea was investigator-reported. The primary outcome was a composite of worsening HF or cardiovascular death. The prevalence of sleep apnea was 5.7% and 7.8% in patients with HFrEF and HFmrEF/HFpEF, respectively. The primary outcome occurred at a rate of 16.0 in participants with sleep apnea compared to 10.6 per 100 person-years in those without (adjusted HR 1.29 [95%CI, 1.10–1.52]). Compared with placebo, dapagliflozin reduced the risk of the primary endpoint to the same extent in patients with (HR 0.78 [95% CI, 0.59–1.03]) and without sleep apnea (HR 0.79 [0.72–0.87]) [P interaction = 0.93]. The beneficial effects of dapagliflozin on other clinical outcomes and symptom burden, physical function, and quality of life were consistent in participants with and without sleep apnea. In DAPA-HF and DELIVER, the true prevalence of sleep apnea was likely underestimated. An investigator-reported history of sleep apnea was associated with higher rates of worsening HF events. The benefits of dapagliflozin on clinical outcomes were consistent in patients with and without sleep apnea. Unique identifiers: NCT01920711 In a pooled analysis of the DAPA-HF and DELIVER trials of more than 11,000 patients with heart failure (HF) across the range of ejection fractions, an investigator-reported history of sleep apnea was associated with higher rates of worsening HF events but not mortality. The beneficial effects of dapagliflozin on clinical outcomes were consistent in patients with and without sleep apnea. These findings provide further evidence for dapagliflozin as a new treatment option for patients with heart failure across the range of ejection fractions. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
4. Impact of empagliflozin on first and recurrent events leading to or prolonging hospitalisation in the EMPA-REG OUTCOME trial
- Author
-
Inzucchi, Silvio E., Wanner, Christoph, Fitchett, David, Zinman, Bernard, Anker, Stefan D., Pocock, Stuart J., Mattheus, Michaela, Hantel, Stefan, and Lund, Søren S.
- Published
- 2024
- Full Text
- View/download PDF
5. Operational challenges and mitigation measures during the COVID-19 pandemic–Lessons from DELIVER.
- Author
-
Bhatt, Ankeet S., Lindholm, Daniel, Nilsson, Ann, Zaozerska, Natalia, Claggett, Brian L., Vaduganathan, Muthiah, Kosiborod, Mikhail N., Lam, Carolyn S.P., Hernandez, Adrian F., Martinez, Felipe A., Inzucchi, Silvio E, Shah, Sanjiv J., de Boer, Rudolf A., Desai, Akshay, Jhund, Pardeep S., Langkilde, Anna Maria, Petersson, Magnus, McMurray, John J.V., and Solomon, Scott D.
- Abstract
Catastrophic disruptions in care delivery threaten the operational efficiency and potentially the validity of clinical research efforts, in particular randomized clinical trials. Most recently, the COVID-19 pandemic affected essentially all aspects of care delivery and clinical research conduct. While consensus statements and clinical guidance documents have detailed potential mitigation measures, few real-world experiences detailing clinical trial adaptations to the COVID-19 pandemic exist, particularly among, large, global registrational cardiovascular trials. We outline the operational impact of COVID-19 and resultant mitigation measures in the Dapagliflozin Evaluation to Improve the LIVEs of Patients with Preserved Ejection Fraction Heart Failure (DELIVER) trial, one of the largest and most globally diverse experiences with COVID-19 of any cardiovascular clinical trial to date. Specifically, we address the needed coordination between academic investigators, trial leadership, clinical sites, and the supporting sponsor to ensure the safety of participants and trial staff, to maintain the fidelity of trial operations, and to prospectively adapt statistical analyses plans to evaluate the impact of COVID-19 and the pandemic at large on trial participants. These discussions included key operational issues such as ensuring delivery of study medications, adaptations to study visits, enhanced COVID-19 related endpoint adjudication, and protocol and analytical plan revisions. Our findings may have important implications for establishing consensus on prospective contingency planning in future clinical trials. Clinicaltrial.gov: NCT03619213. NCT03619213. [ABSTRACT FROM AUTHOR]
- Published
- 2023
- Full Text
- View/download PDF
6. Pragmatic trial of messaging to providers about treatment of acute heart failure: The PROMPT-AHF trial.
- Author
-
Ghazi, Lama, O'Connor, Kyle, Yamamoto, Yu, Fuery, Michael, Sen, Sounok, Samsky, Marc, Riello III, Ralph J., Huang, Joanna, Olufade, Temitope, McDermott, James, Inzucchi, Silvio E., Velazquez, Eric J., Wilson, Francis Perry, Desai, Nihar R., and Ahmad, Tariq
- Abstract
Acute Heart failure (AHF) is among the most frequent causes of hospitalization in the United States, contributing to substantial health care costs, morbidity, and mortality. Inpatient initiation of guideline-directed medical therapy (GDMT) is recommended for patients with heart failure with reduced ejection fraction (HFrEF) to reduce the risk of cardiovascular death or HF hospitalization. However, underutilization of GDMT prior to discharge is pervasive, representing a valuable missed opportunity to optimize evidence-based care. The PR agmatic Trial O f Messaging to P roviders about T reatment of A cute H eart F ailure tests the effectiveness of an electronic health record embedded clinical decision support system that informs providers during hospital management about indicated but not yet prescribed GDMT for eligible AHF patients with HFrEF. PR agmatic Trial O f Messaging to P roviders about T reatment of A cute H eart F ailureis an open-label, multicenter, pragmatic randomized controlled trial of 1,012 patients hospitalized with HFrEF. Eligible patients randomized to the intervention group are exposed to a tailored best practice advisory embedded within the electronic health record that alerts providers to prescribe omitted GDMT. The primary outcome is an increase in the proportion of additional GDMT medication classes prescribed at the time of discharge compared to those in the usual care arm. [ABSTRACT FROM AUTHOR]
- Published
- 2023
- Full Text
- View/download PDF
7. Rationale and design of a cluster-randomized pragmatic trial aimed at improving use of guideline directed medical therapy in outpatients with heart failure: PRagmatic trial of messaging to providers about treatment of heart failure (PROMPT-HF).
- Author
-
Ghazi, Lama, Desai, Nihar R., Simonov, Michael, Yamamoto, Yu, O'Connor, Kyle D., Riello, Ralph J., Huang, Joanna, Olufade, Temitope, McDermott, James, Inzucchi, Silvio E., Velazquez, Eric J., Wilson, F. Perry, and Ahmad, Tariq
- Abstract
Heart failure with reduced ejection fraction (HFrEF) is one of the most common chronic illnesses in the United States and carries significant risk of morbidity and mortality. Use of guideline-directed medical therapy (GDMT) for patients with HFrEF has been shown to dramatically improve outcomes, but adoption of these treatments remains generally low. Possible explanations for poor GDMT uptake include lack of knowledge about recommended management strategies and provider reluctance due to uncertainties regarding application of said guidelines to real-world practice. One way to overcome these barriers is by harnessing the electronic health record (EHR) to create patient-centered "best practice alerts" (BPAs) that can guide clinicians to prescribe appropriate medical therapies. If found to be effective, these low-cost interventions can be rapidly applied across large integrated healthcare systems. The PRagmatic Trial Of Messaging to Providers about Treatment of Heart Failure (PROMPT-HF) trial is a pragmatic, cluster randomized controlled trial designed to test the hypothesis that tailored and timely alerting of recommended GDMT in heart failure (HF) will result in greater adherence to guidelines when compared with usual care. PROMPT-HF has completed enrollment of 1,310 ambulatory patients with HFrEF cared for by 100 providers who were randomized to receive a BPA vs usual care. The BPA alerted providers to GDMT recommended for their patients and displayed current left ventricular ejection fraction (LVEF) along with the most recent blood pressure, heart rate, serum potassium and creatinine levels, and estimated glomerular filtration rate. It also linked to an order set customized to the patient that suggests medications within each GDMT class not already prescribed. Our goal is to examine whether tailored EHR-based alerting for outpatients with HFrEF will lead to higher rates of GDMT at 30 days post randomization when compared with usual care. Additionally, we are assessing clinical outcomes such as hospital readmissions and death between the alert versus usual care group. Trial Registration: Clinicaltrials.gov NCT04514458. [ABSTRACT FROM AUTHOR]
- Published
- 2022
- Full Text
- View/download PDF
8. Empagliflozin in Heart Failure With Predicted Preserved Versus Reduced Ejection Fraction: Data From the EMPA-REG OUTCOME Trial.
- Author
-
Savarese, Gianluigi, Uijl, Alicia, Lund, Lars H., Anker, Stefan D., Asselbergs, Folkert, Fitchett, David, Inzucchi, Silvio E., Koudstaal, Stefan, Ofstad, Anne Pernille, Schrage, Benedikt, Vedin, Ola, Wanner, Christoph, Zannad, Faiez, Zwiener, Isabella, and Butler, Javed
- Abstract
Background: In the EMPA-REG OUTCOME trial, ejection fraction (EF) data were not collected. In the subpopulation with heart failure (HF), we applied a new predictive model for EF to determine the effects of empagliflozin in HF with predicted reduced (HFrEF) vs preserved (HFpEF) EF vs no HF.Methods and Results: We applied a validated EF predictive model based on patient baseline characteristics and treatments to categorize patients with HF as being likely to have HF with mid-range EF (HFmrEF)/HFrEF (EF <50%) or HFpEF (EF ≥50%). Cox regression was used to assess the effect of empagliflozin vs placebo on cardiovascular death/HF hospitalization (HHF), cardiovascular and all-cause mortality, and HHF in patients with predicted HFpEF, HFmrEF/HFrEF and no HF. Of 7001 EMPA-REG OUTCOME patients with data available for this analysis, 6314 (90%) had no history of HF. Of the 687 with history of HF, 479 (69.7%) were predicted to have HFmrEF/HFrEF and 208 (30.3%) to have HFpEF. Empagliflozin's treatment effect was consistent in predicted HFpEF, HFmrEF/HFrEF and no-HF for each outcome (HR [95% CI] for the primary outcome 0.60 [0.31-1.17], 0.79 [0.51-1.23], and 0.63 [0.50-0.78], respectively; P interaction = 0.62).Conclusions: In EMPA-REG OUTCOME, one-third of the patients with HF had predicted HFpEF. The benefits of empagliflozin on HF and mortality outcomes were consistent in nonHF, predicted HFpEF and HFmrEF/HFrEF. [ABSTRACT FROM AUTHOR]- Published
- 2021
- Full Text
- View/download PDF
9. Inpatient management of diabetes mellitus
- Author
-
Metchick, Lee N., Petit, William A., Jr., and Inzucchi, Silvio E.
- Subjects
Diabetes -- Care and treatment ,Hospital patients -- Care and treatment ,Health ,Health care industry - Published
- 2002
10. Patterns of glucose-lowering medication use in patients with type 2 diabetes and heart failure. Insights from the Diabetes Collaborative Registry (DCR).
- Author
-
Arnold, Suzanne V., Echouffo-Tcheugui, Justin B., Lam, Carolyn SP, Inzucchi, Silvio E, Tang, Fengming, McGuire, Darren K, Goyal, Abhinav, Maddox, Thomas M, Sperling, Laurence S, Fonarow, Gregg C, Masoudi, Frederick A, Kosiborod, Mikhail, and Lam, Carolyn S P
- Abstract
Background: Optimal glucose-lowering strategies in patients with both heart failure (HF) and type 2 diabetes mellitus (T2D) are not well defined, particularly as novel medication classes emerge.We sought to evaluate current patterns of glucose-lowering medication use in adults with T2D with and without HF.Methods: The DCR is a US-based outpatient registry of adults with diabetes; currently includes 3074 providers in 203 practices. We used hierarchical, modified Poisson regression models to examine the relationship between concomitant HF with use of each glucose-lowering medication class, adjusting for other factors that could impact selection of one medication class over another: age, chronic kidney disease (CKD), coronary artery disease (CAD), number of glucose-lowering medications, and insurance.Results: Among 456,106 adults with T2D, 125,161 (27%) had a diagnosis of HF (30% HFrEF, 15%HFmrEF, 55% HFpEF). Patients with T2D and HF were more likely to be older and male, and to have CAD, atrial fibrillation, and CKD. In the multivariable models, HF was associated with a greater use of insulin (RR 1.39, 95% CI 1.36-1.42) and lower use of thiazolidinediones (RR 0.79, 95% CI 0.74-0.83), SGLT2 inhibitors (RR 0.83, 95% CI 0.79-0.89), and metformin (RR 0.84, 95% CI 0.82-0.86). Among the subgroup of patients with HF, thiazolidinediones, GLP-1 receptor agonists, and SGLT2 inhibitors were used even less often in patients with lower ejection fraction, indicating that both the diagnosis of clinical HF and ejection fraction may influence the choice of glucose-lowering medications.Conclusion: In a large US-based outpatient registry, we found that a quarter of adults with T2D had a diagnosis of HF, which was predominantly HFpEF. Although certain T2D medication use in patients with HF appeared consistent with evidence (less use of thiazolidinediones), others appeared contrary to evidence (less use of metformin and SGLT2 inhibitors). [ABSTRACT FROM AUTHOR]- Published
- 2018
- Full Text
- View/download PDF
11. Design and rationale for the Cardiovascular and Metabolic Effects of Lorcaserin in Overweight and Obese Patients-Thrombolysis in Myocardial Infarction 61 (CAMELLIA-TIMI 61) trial.
- Author
-
Bohula, Erin A., Scirica, Benjamin M., Fanola, Christina, Inzucchi, Silvio E., Keech, Anthony, McGuire, Darren K., Smith, Steven R., Abrahamsen, Tim, Francis, Bruce H., Miao, Wenfeng, Perdomo, Carlos A., Satlin, Andrew, Wiviott, Stephen D., and Sabatine, Marc S.
- Abstract
Objectives: Lorcaserin, a selective serotonin 2C receptor agonist, is an effective pharmacologic weight-loss therapy that improves several cardiovascular risk factors. The long-term clinical cardiovascular and metabolic safety and efficacy in patients with elevated cardiovascular risk are unknown.Research Design and Methods: CAMELLIA-TIMI 61 (NCT02019264) is a randomized, double-blind, placebo-controlled, multinational clinical trial designed to evaluate the safety and efficacy of lorcaserin with regard to major adverse cardiovascular events and progression to diabetes in overweight or obese patients at high cardiovascular risk. Overweight or obese patients either with established cardiovascular disease or with diabetes and at least 1 other cardiovascular risk factor were randomized in a 1:1 ratio to lorcaserin 10 mg twice daily or matching placebo. The primary safety objective is to assess for noninferiority of lorcaserin for the composite end point of cardiovascular death, myocardial infarction, or stroke (major adverse cardiovascular event [MACE]) (with noninferiority defined as the upper bound of a 1-sided 97.5% CI excluding a hazard ratio of 1.4) compared with placebo assessed at an interim analysis with 460 adjudicated events. The efficacy objectives, assessed at study completion, will evaluate the superiority of lorcaserin for the primary composite end point of cardiovascular death, myocardial infarction, stroke, hospitalization for unstable angina, heart failure, or any coronary revascularization (MACE+) and the key secondary end point of conversion to diabetes. Recruitment began in January 2014 and was completed in November 2015 resulting in a total population of 12,000 patients. The trial is planned to continue until at least 1,401 adjudicated MACE+ events are accrued and the median treatment duration exceeds 2.5 years.Conclusion: CAMELLIA-TIMI 61 is investigating the safety and efficacy of lorcaserin for MACEs and conversion to diabetes in overweight or obese patients with established cardiovascular disease or multiple cardiovascular risk factors. [ABSTRACT FROM AUTHOR]- Published
- 2018
- Full Text
- View/download PDF
12. Cardiovascular Mortality Reduction With Empagliflozin in Patients With Type 2 Diabetes and Cardiovascular Disease.
- Author
-
Fitchett, David, Inzucchi, Silvio E, Lachin, John M, Wanner, Christoph, van de Borne, Philippe, Mattheus, Michaela, Johansen, Odd Erik, Woerle, Hans J, Broedl, Uli C, George, Jyothis T, Zinman, Bernard, and EMPA-REG OUTCOME Investigators
- Published
- 2018
- Full Text
- View/download PDF
13. Pulmonary Hypertension Caused by Graves' Thyrotoxicosis(*): Normal Pulmonary Hemodynamics Restored by [sup.131]I Treatment
- Author
-
Nakchbandi, Inaam A., Wirth, Joel A., and Inzucchi, Silvio E.
- Subjects
Graves' disease -- Complications and side effects ,Hyperthyroidism -- Complications and side effects ,Pulmonary hypertension -- Causes of -- Complications and side effects ,Health ,Complications and side effects ,Causes of - Abstract
Normal Pulmonary Hemodynamics Restored by [sup.131]I Treatment We describe a case of pulmonary hypertension, initially though to be idiopathic, which resolved after treatment of Graves' hyperthyroidism. Results of pulmonary artery [...]
- Published
- 1999
14. Predictors of Major Adverse Limb Events After Infrainguinal Bypass in Patients with Diabetes.
- Author
-
Alameddine, Dana, Satam, Keyuree, Slade, Martin, Wang, He, Mena-Hurtado, Carlos, Turner, Jeffrey, Inzucchi, Silvio E, and Chaar, Cassius Iyad Ochoa
- Abstract
Diabetes mellitus is a major risk factor for peripheral artery disease (PAD). The association of diabetes with major adverse limb events (MALE) after lower extremity revascularization (LER) remains controversial as patients with diabetes are often analyzed as a homogenous group. This study examines the impact of insulin use and glucose control on the outcomes of infrainguinal bypass. Our hypothesis is that insulin therapy and hemoglobin A1c (A1c) are predictors of MALE and might be used to stratify outcomes in of LER in patients with diabetes. The Vascular Quality Initiative (VQI) database for infrainguinal bypass (2007-2021) was reviewed. Patients with diabetes undergoing bypass for PAD were included. Patients on dialysis or with kidney transplant were excluded. The characteristics and outcomes of patients with insulin requiring diabetes mellitus (IRDM) were compared with patients not requiring insulin (NIRDM). A total of 9,686 patients with diabetes (56% IRDM) underwent bypass. Patients with IRDM were significantly younger than patients with NIRDM and more likely to be female, African American, and Hispanic. After a mean follow-up of 427 days post-operation, patients with IRDM had significantly lower primary patency and higher major amputation, MALE, and mortality. (Table) Regression analyses demonstrated that insulin use, but not A1c, was independently associated with higher risk of MALE (HR = 1.17 [1.06-1.29]) and mortality (HR=1.28 [1.16-1.43]). Prevalent insulin use, but not the degree of A1c control, is a significant predictor of MALE and survival after infrainguinal bypass and should be used to stratify the outcomes of LER in patients with diabetes. [ABSTRACT FROM AUTHOR]
- Published
- 2022
- Full Text
- View/download PDF
15. Dethroning the king?: The future of metformin as first line therapy in type 2 diabetes.
- Author
-
Inzucchi, Silvio E. and Fonseca, Vivian
- Published
- 2019
- Full Text
- View/download PDF
16. Central vs site outcome adjudication in the IRIS trial.
- Author
-
Forman, Rachel, Viscoli, Catherine M., Bath, Philip M., Furie, Karen L., Guarino, Peter, Inzucchi, Silvio E., Young, Lawrence, and Kernan, Walter N.
- Abstract
Background: Central adjudication of outcome events is the standard in clinical trial research. We examine the benefit of central adjudication in the Insulin Resistance Intervention after Stroke (IRIS) trial and show how the benefit is influenced by outcome definition and features of the adjudicated events.Methods: IRIS tested pioglitazone for prevention of stroke and myocardial infarction in patients with a recent transient ischemic attack or ischemic stroke. We compared the hazard ratios for study outcomes classified by site and central adjudication. We repeated the analysis for an updated stroke definition.Results: The hazard ratios for the primary outcome were identical (0.76) and statistically significant regardless of adjudicator. The hazard ratios for stroke alone were nearly identical with site and central adjudication, but only reached significance with site adjudication (HR, 0.80; p = 0.049 vs. HR, 0.82; p = 0.09). Using the updated stroke definition, all hazard ratios were lower than with the original IRIS definition and statistically significant regardless of adjudication method. Agreement was higher when stroke type was certain, subtype was large vessel or cardioembolic, signs or symptoms lasted > 24 h, imaging showed a stroke, and when NIHSS was ≥3.Discussion: Central stroke adjudication caused the hazard ratio for a main secondary outcome in IRIS (stroke alone) to be higher and lose statistical significant compared with site review. The estimate of treatment effects were larger with the updated stroke definition. There may be benefit of central adjudication for events with specific features, such as shorter symptom duration or normal brain imaging. [ABSTRACT FROM AUTHOR]- Published
- 2022
- Full Text
- View/download PDF
17. How well do glucose variability measures predict patient glycaemic outcomes during treatment intensification in type 2 diabetes?
- Author
-
Inzucchi, Silvio E., Umpierrez, Guillermo, DiGenio, Andres, Zhou, Rong, and Kovatchev, Boris
- Subjects
- *
TYPE 2 diabetes treatment , *STATISTICAL correlation , *HEMOGLOBINS , *GLYCEMIC index , *BODY mass index , *STATISTICAL significance , *HEALTH outcome assessment , *BLOOD sugar analysis , *BLOOD sugar , *CLINICAL trials , *GLYCOSYLATED hemoglobin , *HYPOGLYCEMIC agents , *LONGITUDINAL method , *TYPE 2 diabetes , *TIME , *THERAPEUTICS - Abstract
Aim: Despite links to clinical outcomes in patients with type 2 diabetes mellitus (T2DM), the clinical utility of glycaemic variability (GV) measures is unknown. We evaluated the correlation between baseline GV, and glycated haemoglobin (HbA1c) attainment and hypoglycaemic events during treatment intensification in a large group of patients.Methods: Patient-level data from six 24-week clinical trials of T2DM patients undergoing treatment intensification with basal insulin or comparators (N = 1699) were pooled. Baseline GV measures included standard deviation (SD), mean amplitude of glycaemic excursions (MAGE), mean absolute glucose (MAG), coefficient of variation (CV), high blood glucose index (HBGI), and low blood glucose index (LBGI) and were correlated with HbA1c change and hypoglycaemic events.Results: All mean GV measures, excluding CV which worsened, improved significantly from baseline to Week 24, with the largest proportional reduction obtained for HBGI (-65.5%). When assessed as mean individual percentage changes, only HBGI improved significantly. Baseline GV correlated positively with Week 24 HbA1c for SD, MAGE, and HBGI. Baseline HBGI and CV correlated negatively and positively, respectively, with Week 24 HbA1c change. Correlations also existed between most baseline GV measures and age, body mass index, Week 24 fasting plasma glucose, Week 24 postprandial plasma glucose, and hypoglycaemic events; statistical significance depended on the specific measure.Conclusions: Pre-treatment GV is associated with glycaemic outcomes in T2DM patients undergoing treatment intensification over 24 weeks. HBGI might be the most robust predictor, warranting validation in dedicated prospective studies or randomized trials to assess the predictive value of measuring GV. [ABSTRACT FROM AUTHOR]- Published
- 2015
- Full Text
- View/download PDF
18. Association Of Kidney And Cardiovascular Outcomes: Insights From The Empagliflozin Cardiovascular Outcome Event Trial In Type 2 Diabetes Mellitus Patients (EMPA-REG OUTCOME) Trial.
- Author
-
Sharma, Abhinav, Inzucchi, Silvio E., Testani, Jeffrey, Ofstad, Anne-Pernille, Fitchett, David, Mattheus, Michaela, Verma, Subodh, Zannad, Faiez, Wanner, Christoph, and Kraus, Bettina J.
- Abstract
Cardiovascular and kidney disease are closely inter-related. In EMPA-REG OUTCOME, empagliflozin (10 or 25mg once daily) reduced the risk of hospitalization for heart failure (HHF) and kidney events in patients with type 2 diabetes and established cardiovascular (CV) disease. We evaluated whether kidney events increase risk for subsequent HF or CV outcomes and vice versa. Bi-directional associations of kidney events and subsequent CV events were explored using Cox regression with time-varying covariates. Of 2,061 placebo patients, 18.8% experienced a kidney event (progression to macroalbuminuria with urine albumin-creatinine ratio [UACR] >300mg/g, doubling of serum creatinine with estimated glomerular filtration rate [eGFR] ≤45 ml/min/1.73 m
2 , initiation of renal-replacement therapy or renal death). Factors significantly associated with risk of experiencing a kidney event included: low baseline eGFR, albuminuria ≥30mg/g, high uric acid and LDL-C, prior HF but no coronary artery disease. In placebo patients, occurrence of a non-fatal kidney event increased subsequent HHF risk (hazard ratio [95% CI]) (2.40 [1.42,4.05]) but not 3P-MACE (1.30 [0.89,1.91]) (panel A). Vice versa, HHF (2.03 [1.22,3.39]) but not myocardial infarction (MI)/stroke (0.94 [0.56,1.56]) increased subsequent kidney event risk in the placebo arm (panel B). For 3-P MACE following kidney event, risk was significantly increased in the empagliflozin and overall groups although to a lesser extent and not significant from placebo (panel A). These findings demonstrate strong bi-directional inter-relationship between HHF and kidney events. Strategies to optimize the use of therapies such as empagliflozin, reducing both kidney and HF outcomes, are warranted, as their benefits may be compounded. [ABSTRACT FROM AUTHOR]- Published
- 2022
- Full Text
- View/download PDF
19. Inpatient Management of Diabetes and Hyperglycemia.
- Author
-
Bogun, Magdalena and Inzucchi, Silvio E.
- Subjects
- *
TREATMENT of diabetes , *HYPERGLYCEMIA treatment , *INSULIN therapy , *ALGORITHMS , *CRITICALLY ill , *MEDICAL protocols , *PATIENTS , *PARENTERAL infusions - Abstract
Illness, particularly when severe, leads to increased concentrations of counter-regulatory factors which induce insulin resistance and predispose patients to stress hyperglycemia. Elevated glucose concentrations are common in hospitalized patients, both those with as well as without recognized diabetes. Substantial data has emerged over the past decade that quality glucose management in these individuals actually improves clinical outcomes. Controlling glucose in this setting is challenging, given the phenotypic variability amongst patients, with fluctuating courses of acute illnesses and unpredictable nutritional schedules. We review the evidence basis that has informed national standards and glucose targets in both critically and non-critically ill patients. In the intensive care setting, insulin infusions are now widely endorsed to quickly achieve and maintain glucose control. On the hospital wards, physiological subcutaneous insulin therapy, incorporating both basal and nutritional components, is emerging as the optimal treatment strategy. The transition to outpatient care is another important aspect of any hospital glycemic management program. [ABSTRACT FROM AUTHOR]
- Published
- 2013
- Full Text
- View/download PDF
20. Diabetes Mellitus and Heart Failure: Epidemiology, Mechanisms, and Pharmacotherapy
- Author
-
Masoudi, Frederick A. and Inzucchi, Silvio E.
- Subjects
- *
ENDOCRINE diseases , *HEART diseases , *HEART failure , *INFECTIOUS disease transmission - Abstract
Diabetes mellitus and heart failure (HF), both of which are associated with high rates of adverse cardiovascular outcomes, commonly coexist. Given the marked increases in diabetes prevalence in developed countries, the proportion of the population with both conditions is likely to increase substantially. This article reviews the epidemiology of HF and diabetes, the mechanisms whereby diabetes causes HF, and the pharmacotherapy of both HF and diabetes. Specific challenges in treating patients with both HF and diabetes are also addressed. [Copyright &y& Elsevier]
- Published
- 2007
- Full Text
- View/download PDF
21. Dapagliflozin and Days of Full Health Lost in the DAPA-HF Trial.
- Author
-
Kondo, Toru, Mogensen, Ulrik M., Talebi, Atefeh, Gasparyan, Samvel B., Campbell, Ross T., Docherty, Kieran F., de Boer, Rudolf A., Inzucchi, Silvio E., Køber, Lars, Kosiborod, Mikhail N., Martinez, Felipe A., Sabatine, Marc S., Bengtsson, Olof, Sjöstrand, Mikaela, Vaduganathan, Muthiah, Solomon, Scott D., Jhund, Pardeep S., and McMurray, John J.V.
- Subjects
- *
DAPAGLIFLOZIN , *VENTRICULAR ejection fraction , *HEART failure patients , *HEART failure ,CARDIOVASCULAR disease related mortality - Abstract
Conventional time-to-first-event analyses cannot incorporate recurrent hospitalizations and patient well-being in a single outcome. To overcome this limitation, we tested an integrated measure that includes days lost from death and hospitalization, and additional days of full health lost through diminished well-being. The effect of dapagliflozin on this integrated measure was assessed in the DAPA-HF (Dapagliflozin and Prevention of Adverse Outcomes in Heart Failure) trial, which examined the efficacy of dapagliflozin, compared with placebo, in patients with NYHA functional class II to IV heart failure and a left ventricular ejection fraction ≤40%. Over 360 days, patients in the dapagliflozin group (n = 2,127) lost 10.6 ± 1.0 (2.9%) of potential follow-up days through cardiovascular death and heart failure hospitalization, compared with 14.4 ± 1.0 days (4.0%) in the placebo group (n = 2,108), and this component of all measures of days lost accounted for the greatest between-treatment difference (−3.8 days [95% CI: −6.6 to −1.0 days]). Patients receiving dapagliflozin also had fewer days lost to death and hospitalization from all causes vs placebo (15.5 ± 1.1 days [4.3%] vs 20.3 ± 1.1 days [5.6%]). When additional days of full health lost (ie, adjusted for Kansas City Cardiomyopathy Questionnaire–overall summary score) were added, total days lost were 110.6 ± 1.6 days (30.7%) with dapagliflozin vs 116.9 ± 1.6 days (32.5%) with placebo. The difference in all measures between the 2 groups increased over time (ie, days lost by death and hospitalization −0.9 days [−0.7%] at 120 days, −2.3 days [−1.0%] at 240 days, and −4.8 days [−1.3%] at 360 days). Dapagliflozin reduced the total days of potential full health lost due to death, hospitalizations, and impaired well-being, and this benefit increased over time during the first year. (Study to Evaluate the Effect of Dapagliflozin on the Incidence of Worsening Heart Failure or Cardiovascular Death in Patients With Chronic Heart Failure; NCT03036124) [Display omitted] [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
22. Efficacy of Sotagliflozin in Adults With Type 2 Diabetes in Relation to Baseline Hemoglobin A1c.
- Author
-
Aggarwal, Rahul, Bhatt, Deepak L., Szarek, Michael, Cannon, Christopher P., McGuire, Darren K., Inzucchi, Silvio E., Lopes, Renato D., Davies, Michael J., Banks, Phillip, Pitt, Bertram, and Steg, Philippe Gabriel
- Subjects
- *
TYPE 2 diabetes , *GLYCOSYLATED hemoglobin , *PROPORTIONAL hazards models , *HEMOGLOBINS , *ADULTS - Abstract
The SCORED (Effect of Sotagliflozin on Cardiovascular and Renal Events in Patients with Type 2 Diabetes and Moderate Renal Impairment Who Are at Cardiovascular Risk) and SOLOIST-WHF (Effect of Sotagliflozin on Cardiovascular Events in Patients with Type 2 Diabetes Post Worsening Heart Failure) trials demonstrated that sotagliflozin, an SGLT1 and SGLT2 inhibitor, improves outcomes in individuals with type 2 diabetes who have heart failure (HF) or kidney disease. We assessed the efficacy of sotagliflozin on HF clinical outcomes in individuals with differing baseline glycosylated hemoglobin (HbA1c) levels. We included all adults from SCORED and SOLOIST-WHF. The primary outcome was a composite of cardiovascular death, hospitalizations for HF, and urgent visits for HF. The efficacy of sotagliflozin compared with placebo was evaluated by baseline HbA1c using competing-risk marginal proportional hazards models. We identified 11,744 adults. Individuals with HbA1c ≤7.5% experienced the primary outcome at a lower rate in the sotagliflozin group (11.2 per 100 person-years) than the placebo group (15.5 per 100 person-years) (HR: 0.73; 95% CI: 0.57-0.93). Similarly, individuals with HbA1c of 7.6% to 9.0% experienced the primary outcome at a lower rate in the sotagliflozin group (7.3 per 100 person-years) than the placebo group (9.4 per 100 person-years) (HR: 0.77; 95% CI: 0.63-0.96). These findings were also consistent among individuals with HbA1c >9.0%, with a primary outcome rate in the sotagliflozin group (7.8 per 100 person-years) that was lower than the placebo group (11.6 per 100 person-years) (HR: 0.65; 95% CI: 0.50-0.84). The efficacy of sotagliflozin was consistent by baseline HbA1c level (P for interaction = 0.58). In individuals with type 2 diabetes and either HF or kidney disease, sotagliflozin reduced HF outcomes irrespective of baseline HbA1c. [Display omitted] [ABSTRACT FROM AUTHOR]
- Published
- 2023
- Full Text
- View/download PDF
23. Dapagliflozin in Patients With Heart Failure and Deterioration in Renal Function.
- Author
-
Chatur, Safia, Vaduganathan, Muthiah, Claggett, Brian L., Mc Causland, Finnian R., Desai, Akshay S., Jhund, Pardeep S., de Boer, Rudolf A., Hernandez, Adrian F., Inzucchi, Silvio E., Kosiborod, Mikhail N., Lam, Carolyn S.P., Martinez, Felipe A., Shah, Sanjiv J., Sabatine, Marc S., Kober, Lars, Ponikowski, Piotr, Merkely, Bela, Petersson, Magnus, Langkilde, Anna Maria, and McMurray, John J.V.
- Subjects
- *
HEART failure patients , *DAPAGLIFLOZIN , *KIDNEY physiology , *PROPORTIONAL hazards models , *KIDNEY failure - Abstract
Sodium-glucose cotransporter-2 (SGLT2) inhibitors are guideline recommended in the management of heart failure (HF). Although these therapies can be initiated even in patients with comorbid chronic kidney disease, some patients may face deterioration of kidney function over time. In this study, the authors sought to examine the safety and efficacy of continuing SGLT2 inhibitors in HF when the estimated glomerular filtration rate (eGFR) falls below thresholds for initiation. Associations between a deterioration of eGFR to <25 mL/min/1.73 m2, efficacy, and safety outcomes and treatment with dapagliflozin were evaluated in time-updated Cox proportional hazard models in a participant-level pooled analysis of the DAPA-HF (Study to Evaluate the Effect of Dapagliflozin on the Incidence of Worsening Heart Failure or Cardiovascular Death in Patients With Chronic Heart Failure) and DELIVER (Dapagliflozin Evaluation to Improve the Lives of Patients With Preserved Ejection Fraction Heart Failure) trials. Among 11,007 patients, 347 (3.2%) experienced a deterioration of eGFR to <25 mL/min/1.73 m2 at least once in follow-up. These patients had a higher risk of the primary composite outcome (HR: 1.87; 95% CI: 1.48-2.35; P < 0.001). The risk of the primary outcome was lower with dapagliflozin compared with placebo among patients who did (HR: 0.53; 95% CI: 0.33-0.83) as well as did not (HR: 0.78; 95% CI: 0.72-0.86) experience deterioration of eGFR to <25 mL/min/1.73 m2 (P interaction = 0.17). The risk of safety outcomes, including drug discontinuation, was higher among patients with deterioration of eGFR to <25 mL/min/1.73 m2; however, rates remained similar between treatment groups including among those who remained on study drug. Patients with deterioration of eGFR to <25 mL/min/1.73 m2 had elevated risks of cardiovascular outcomes yet appeared to benefit from continuation of dapagliflozin with no excess in safety outcomes between treatment groups. The benefit-to-risk ratio may favor continuation of dapagliflozin treatment in patients with HF experiencing deterioration of kidney function. Study to Evaluate the Effect of Dapagliflozin on the Incidence of Worsening Heart Failure or Cardiovascular Death in Patients With Chronic Heart Failure [DAPA-HF]; NCT03036124 ; and Dapagliflozin Evaluation to Improve the Lives of Patients With Preserved Ejection Fraction Heart Failure [DELIVER]; NCT03619213) [Display omitted] [ABSTRACT FROM AUTHOR]
- Published
- 2023
- Full Text
- View/download PDF
24. EMPAGLIFLOZIN REDUCES MORTALITY AND HOSPITALIZATION FOR HEART FAILURE IN PATIENTS WITH OR WITHOUT A HISTORY OF MYOCARDIAL INFARCTION OR STROKE AT BASELINE.
- Author
-
Fitchett, David H., Inzucchi, Silvio E., Sambevski, Steven, Kaspers, Stefan, Pfarr, Egon, George, Jyothis T., and Zinman, Bernard
- Published
- 2018
- Full Text
- View/download PDF
25. Efficacy of Dapagliflozin According to Geographic Location of Patients With Heart Failure.
- Author
-
Kondo, Toru, Wang, Xiaowen, Yang, Mingming, Jhund, Pardeep S., Claggett, Brian L., Vaduganathan, Muthiah, Hernandez, Adrian F., Lam, Carolyn S.P., Inzucchi, Silvio E., Martinez, Felipe A., de Boer, Rudolf A., Kosiborod, Mikhail N., Desai, Akshay S., Køber, Lars, Ponikowski, Piotr, Sabatine, Marc S., Langkilde, Anna Maria, Petersson, Magnus, Zaozerska, Natalia, and Bachus, Erasmus
- Subjects
- *
HEART failure , *HEART failure patients , *DAPAGLIFLOZIN , *VENTRICULAR ejection fraction ,CARDIOVASCULAR disease related mortality - Abstract
Because clinical characteristics and prognosis vary by geographic region in patients with heart failure (HF), the response to treatment may also vary. A previous report suggested that the efficacy of sodium-glucose cotransporter-2 inhibitor efficacy in heart failure with reduced ejection fraction (HFrEF) may be modified by region. The goal of this study was to examine the efficacy and safety of dapagliflozin in patients with HF according to geographic region. We conducted a patient-level pooled analysis of the DAPA-HF (Dapagliflozin and Prevention of Adverse Outcomes in Heart Failure) and DELIVER (Dapagliflozin Evaluation to Improve the Lives of Patients with Preserved Ejection Fraction Heart Failure) trials, which evaluated the effects of dapagliflozin in HFrEF and heart failure with mildly reduced ejection fraction (HFmrEF)/heart failure with preserved ejection fraction (HFpEF), respectively. The primary outcome was the composite of worsening HF or cardiovascular death. Among 11,007 patients, 5,159 (46.9%) were enrolled in Europe, 1,528 (13.9%) in North America, 1,998 (18.2%) in South America, and 2,322 (21.1%) in Asia. The rate of the primary outcome (per 100 person-years) was higher in North America (13.9 [95% CI: 12.5-15.4]) than in other regions: Europe 10.8 (95% CI: 10.1-11.5), South America 10.0 (95% CI: 9.0-11.1), and Asia 10.5 (95% CI: 9.5-11.5). The benefit of dapagliflozin on the primary outcome was not modified by region: dapagliflozin vs placebo HR: Europe, 0.85 (95% CI: 0.75-0.96); North America, 0.75 (95% CI: 0.61-0.93); South America, 0.72 (95% CI: 0.58-0.89); and Asia, 0.74 (95% CI: 0.61-0.91) (P interaction = 0.40). This was the same when evaluated separately for HFrEF (P interaction = 0.39) and HFmrEF/HFpEF (P interaction = 0.84). Patients in North America discontinued randomized treatment more frequently than did those elsewhere (placebo discontinuation: 21.8% in North America vs 6.4% in South America), but discontinuation rates did not differ between placebo and dapagliflozin by region. The efficacy and safety of dapagliflozin were consistent across global regions despite geographic differences in patient characteristics, background treatment, and event rates. [Display omitted] [ABSTRACT FROM AUTHOR]
- Published
- 2023
- Full Text
- View/download PDF
26. CONSISTENT EFFECT OF EMPAGLIFLOZIN ON COMPOSITE OUTCOMES RELATED TO HEART FAILURE: RESULTS FROM EMPA-REG OUTCOME.
- Author
-
Inzucchi, Silvio E., Zinman, Bernard, McGinniss, Jennifer, Schnee, Janet, George, Jyothis, and Fitchett, David
- Subjects
- *
HEART failure - Published
- 2017
- Full Text
- View/download PDF
27. Assessing use of patient-focused pharmacotherapy in glycemic management through the Diabetes Collaborative Registry (DCR).
- Author
-
Arnold, Suzanne V., McGuire, Darren K., Inzucchi, Silvio E., Tang, Fengming, Mehta, Sanjeev N., Lam, Carolyn S.P., Goyal, Abhinav, Sperling, Laurence S., Wong, Nathan D., Hammar, Niklas, Fenici, Peter, and Kosiborod, Mikhail
- Abstract
Background: Although practice guidelines stress individualization of glucose management in patients with type 2 diabetes (T2D), the extent to which providers take patient factors into account when selecting medications is not well known.Methods: Diabetes Collaborative Registry (DCR) is an outpatient diabetes registry including primary care, cardiology, and endocrinology practices. T2D medications were grouped as those which may be suboptimal for key patient subgroups, and we examined patient factors associated with use of these agents using hierarchical, multivariable Poisson models.Results: In DCR, 157,551 patients from 374 US practices were prescribed a glucose-lowering medication. Patients with morbid obesity were more likely treated with medications prone to cause weight gain (relative rate [RR] 1.09, 95% CI 1.07-1.11). Older patients were more likely to be treated with medications with increased risk of hypoglycemia (RR 1.04 per 5 years, 95% CI 1.04-1.05). Patients with CKD 4/5 were less likely to be treated with agents with known risk in patients with advanced CKD (RR 0.74, 95% CI 0.71-0.77). Patients with coronary artery disease were no more or less likely to be treated with medications with potential cardiovascular safety issues (RR 0.99, 95% CI 0.96-1.01).Conclusions: We observed some targeted use of glucose-lowering therapies in certain subgroups but also identified potential opportunities for better personalization of treatment. Data sources such as the DCR can highlight potential areas for improving targeted approaches to pharmacologic therapy in order to optimize selection of patients most likely to benefit (and least likely to be harmed) from treatments. [ABSTRACT FROM AUTHOR]- Published
- 2018
- Full Text
- View/download PDF
28. Glucose-Lowering Medications and Angina Burden in Patients with Stable Coronary Disease: results from the Type 2 Diabetes Evaluation of Ranolazine in Subjects With Chronic Stable Angina (TERISA) Trial.
- Author
-
Arnold, Suzanne V., McGuire, Darren K., Spertus, John A., Tang, Fengming, Yue, Patrick, Inzucchi, Silvio E., Belardinelli, Luiz, Chaitman, Bernard R., and Kosiborod, Mikhail
- Abstract
Background: Different classes of glucose-lowering medications have been associated with varying risks of myocardial infarction and cardiovascular death, but their effect on angina is unknown. Therefore, we sought to determine the association of different glucose-lowering medication classes with angina frequency and nitroglycerin (NTG) use.Methods: We performed a secondary, observational analysis of the TERISA multinational trial, which evaluated the antianginal effect of ranolazine versus placebo in patients with type 2 diabetes mellitus, documented coronary disease, and a 3-month history of stable angina. Patients recorded angina and NTG use in a daily dairy for 3 weeks prior to randomization, to establish their baseline angina burden for the trial. We then examined the association of different glucose-lowering medication classes with baseline angina and NTG use using multivariable linear regression.Results: Among 952 patients enrolled, 494 were taking metformin, 504 taking a sulfonylurea, 186 taking insulin, 29 taking DPP-4 inhibitors, 22 taking other glucose-lowering medications, and 68 were diet-controlled only. After adjustment for demographic and clinical factors, patients taking versus not taking sulfonylureas had 1.02 more episodes of angina and used 0.93 more doses of NTG per week (P = .002 and .011, respectively). The weekly angina burden or NTG use was not different for those taking versus not taking metformin (P > .7 for both). Patients taking versus not taking insulin had 0.83 more episodes of angina and used 1.40 more NTG doses per week, increases evident only in those taking insulin without concomitant metformin (Pinteraction < .05 for both).Conclusion: Different classes of glucose-lowering medications were associated with varying angina burden in patients with type 2 diabetes mellitus and stable coronary disease. Patients taking sulfonylureas or insulin had more angina and used more NTG, while metformin was not associated with angina burden. Given the increasing prevalence of glucose abnormalities in patients with coronary disease, a better understanding of the relationship between glucose-lowering medications and angina is needed. [ABSTRACT FROM AUTHOR]- Published
- 2015
- Full Text
- View/download PDF
29. Clarification—Improving Glycemic Control in the Cardiothoracic Intensive Care Unit: Clinical Experience in Two Hospital Settings.
- Author
-
Goldberg, Philip A. and Inzucchi, Silvio E.
- Published
- 2005
- Full Text
- View/download PDF
30. Pioglitazone for secondary prevention after ischemic stroke and transient ischemic attack: Rationale and design of the Insulin Resistance Intervention after Stroke Trial.
- Author
-
Viscoli, Catherine M., Brass, Lawrence M., Carolei, Antonio, Conwit, Robin, Ford, Gary A., Furie, Karen L., Gorman, Mark, Guarino, Peter D., Inzucchi, Silvio E., Lovejoy, Anne M., Parsons, Mark W., Peduzzi, Peter N., Ringleb, Peter A., Schwartz, Gregory G., Spence, J. David, Tanne, David, Young, Lawrence H., and Kernan, Walter N.
- Abstract
Background Recurrent vascular events remain a major source of morbidity and mortality after stroke or transient ischemic attack (TIA). The IRIS Trial is evaluating an approach to secondary prevention based on the established association between insulin resistance and increased risk for ischemic vascular events. Specifically, IRIS will test the effectiveness of pioglitazone, an insulin-sensitizing drug of the thiazolidinedione class, for reducing the risk for stroke and myocardial infarction (MI) among insulin resistant, nondiabetic patients with a recent ischemic stroke or TIA. Design Eligible patients for IRIS must have had insulin resistance defined by a Homeostasis Model Assessment–Insulin Resistance >3.0 without meeting criteria for diabetes. Within 6 months of the index stroke or TIA, patients were randomly assigned to pioglitazone (titrated from 15 to 45 mg/d) or matching placebo and followed for up to 5 years. The primary outcome is time to stroke or MI. Secondary outcomes include time to stroke alone, acute coronary syndrome, diabetes, cognitive decline, and all-cause mortality. Enrollment of 3,876 participants from 179 sites in 7 countries was completed in January 2013. Participant follow-up will continue until July 2015. Summary The IRIS Trial will determine whether treatment with pioglitazone improves cardiovascular outcomes of nondiabetic, insulin-resistant patients with stroke or TIA. Results are expected in early 2016. [ABSTRACT FROM AUTHOR]
- Published
- 2014
- Full Text
- View/download PDF
31. Temporal trends and hospital variation in the management of severe hyperglycemia among patients with acute myocardial infarction in the United States.
- Author
-
Venkitachalam, Lakshmi, McGuire, Darren K., Gosch, Kensey, Lipska, Kasia, Inzucchi, Silvio E., Lind, Marcus, Goyal, Abhinav, Spertus, John A., Masoudi, Frederick A., Jones, Philip G., and Kosiborod, Mikhail
- Abstract
Background: Elevated blood glucose is associated with higher mortality in patients with acute myocardial infarction (AMI). Although clinical guidelines recommend targeted glucose control in this group, clinical trials have yielded inconclusive results. Our objective was to understand how this lack of evidence impacts the management of severe hyperglycemia in routine practice. Methods: We examined insulin use among 4,297 AMI admissions with a mean hospitalization blood glucose of ≥200 mg/dL across 55 US hospitals from 2000 to 2008. Temporal trends and interhospital variation in 2 measures of insulin use during hospitalization—any (subcutaneous, intravenous [IV], short acting, long acting) and IV insulin—were examined using hierarchical Poisson regression models. Results: Of the 4,297 admissions, 2,618 (61%) received any insulin and 538 (13%) received IV insulin. After multivariable adjustment, a slight increase in insulin use was observed per admission year (relative risk [RR] 1.06, 95% CI 1.01-1.11). There was a modest (albeit nonsignificant) increase in IV insulin use seen before May 2004 (RR 1.18, 95% CI 0.96-1.47), with no significant change thereafter (RR 0.99, 95% CI 0.92-1.09). Marked variability in insulin use was observed across hospitals (median rate ratio 1.5 [any insulin] and 1.8 [IV insulin]), which did not change over time. Conclusions: Insulin use among patients with AMI and severe hyperglycemia has remained low over the past decade, with substantial and persistent interhospital variation. These observations reflect marked clinical uncertainty with regard to glucose management in AMI, underscoring the imperative for a definitive clinical trial in this field. [Copyright &y& Elsevier]
- Published
- 2013
- Full Text
- View/download PDF
32. Effect of Dapagliflozin on Health Status in Patients With Preserved or Mildly Reduced Ejection Fraction.
- Author
-
Kosiborod, Mikhail N., Bhatt, Ankeet S., Claggett, Brian L., Vaduganathan, Muthiah, Kulac, Ian J., Lam, Carolyn S.P., Hernandez, Adrian F., Martinez, Felipe A., Inzucchi, Silvio E., Shah, Sanjiv J., de Boer, Rudolf A., Jhund, Pardeep S., Desai, Akshay S., Fang, James C., Han, Yaling, Comin-Colet, Josep, Vardeny, Orly, Lindholm, Daniel, Wilderäng, Ulrica, and Bengtsson, Olof
- Subjects
- *
HEART failure , *VENTRICULAR ejection fraction , *DAPAGLIFLOZIN , *HEART failure patients , *PATIENTS' attitudes , *CLINICAL deterioration - Abstract
Patients with heart failure with mildly reduced ejection fraction (HFmrEF) and heart failure with preserved ejection fraction (HFpEF) experience a high burden of symptoms, physical limitations, and poor quality of life; improving health status is a key goal of management. In a prespecified analysis of the DELIVER (Dapagliflozin Evaluation to Improve the Lives of Patients With Preserved Ejection Fraction Heart Failure) trial, we examine effects of dapagliflozin on health status using the Kansas City Cardiomyopathy Questionnaire (KCCQ). The DELIVER trial randomized patients with symptomatic HFmrEF/HFpEF to dapagliflozin 10 mg or placebo. KCCQ was evaluated at randomization, 1, 4, and 8 months; KCCQ Total Symptom Score (TSS) was a key secondary endpoint. Patients were stratified by KCCQ-TSS tertiles; Cox models examined effects of dapagliflozin on clinical outcomes. We evaluated the effects of dapagliflozin on KCCQ-TSS, Physical Limitations (PLS), Clinical Summary (CSS), and Overall Summary (OSS) domains. Responder analyses compared proportions of dapagliflozin vs placebo-treated patients with clinically meaningful changes in KCCQ. A total of 5,795 patients had baseline KCCQ (median KCCQ-TSS 72.9). The effects of dapagliflozin on reducing cardiovascular death/worsening HF appeared more pronounced in patients with greater baseline symptom burden (lowest-to-highest KCCQ-TSS tertile: HR: 0.70 [95% CI: 0.58-0.84]; 0.81 [95% CI: 0.65-1.01]; 1.07 [95% CI: 0.83-1.37]; P interaction = 0.026). Dapagliflozin improved KCCQ-TSS, -PLS, -CSS, and -OSS at 8 months (2.4, 1.9, 2.3, and 2.1 points higher vs placebo; P < 0.001 for all). Dapagliflozin-treated patients experienced improvements in KCCQ-TSS regardless of EF (P interaction = 0.85). Fewer dapagliflozin-treated patients had deterioration, and more had improvements in all KCCQ domains at 8 months. The clinical benefits of dapagliflozin in HFmrEF/HFpEF appear especially pronounced in those with greater baseline symptom impairment. Dapagliflozin improved all KCCQ domains and the proportion of patients experiencing clinically meaningful changes in health status. (Dapagliflozin Evaluation to Improve the LIVEs of Patients With PReserved Ejection Fraction Heart Failure [DELIVER]; NCT03619213) [Display omitted] [ABSTRACT FROM AUTHOR]
- Published
- 2023
- Full Text
- View/download PDF
33. Estimated Long-Term Benefit of Dapagliflozin in Patients With Heart Failure.
- Author
-
Vaduganathan, Muthiah, Claggett, Brian L., Jhund, Pardeep, de Boer, Rudolf A., Hernandez, Adrian F., Inzucchi, Silvio E., Kosiborod, Mikhail N., Lam, Carolyn S.P., Martinez, Felipe, Shah, Sanjiv J., Desai, Akshay S., Lindholm, Daniel, Petersson, Magnus, Langkilde, Anna Maria, McMurray, John J.V., and Solomon, Scott D.
- Subjects
- *
VENTRICULAR ejection fraction , *DAPAGLIFLOZIN , *MIDDLE age , *OLDER people , *HEART failure , *LEFT heart ventricle , *SODIUM , *TYPE 2 diabetes , *RESEARCH funding , *STROKE volume (Cardiac output) , *GLUCOSE , *HEART physiology - Abstract
Background: Recent guidelines support consideration of sodium-glucose cotransporter-2 inhibitors in the long-term management of heart failure (HF) with mildly reduced or preserved ejection fraction. Patients and clinicians may be interested in the expected lifetime benefits of sodium-glucose cotransporter-2 inhibitors in this population.Objectives: This study aimed to estimate event-free survival gains from long-term use of dapagliflozin in patients with HF with mildly reduced or preserved ejection fraction overall and in clinically relevant subgroups.Methods: In this prespecified analysis of DELIVER (Dapagliflozin Evaluation to Improve the Lives of Patients With Preserved Ejection Fraction Heart Failure), we applied validated nonparametric age-based methods to extrapolate potential gains in survival free from the primary endpoint (cardiovascular death or worsening HF event) from long-term use of dapagliflozin. Eligible participants had symptomatic HF, left ventricular ejection fraction >40%, elevated natriuretic peptide levels, and structural heart disease. For every year between the ages of 55 and 85 years, we estimated event-free survival using age at randomization rather than time from randomization as the time horizon. Residual lifespan free from a primary endpoint was estimated based on area under the survival curve in each arm.Results: Among 6,263 participants, mean survival free from the primary endpoint for a 65-year-old participant was 12.1 years (95% CI: 11.0-13.2 years) with dapagliflozin and 9.7 years (95% CI: 8.8-10.7 years) with placebo, representing a 2.3-year (95% CI: 0.9-3.8 years) event-free survival gain (P = 0.002). Treatment gains in survival free from the primary endpoint ranged from 2.0 years (95% CI: -0.6 to 4.6 years) in a 55-year-old to 1.2 years (95% CI: -0.1 to 2.4 years) in a 75-year-old patient. Mean event-free survival was greater with dapagliflozin than with placebo across all 14 subgroups.Conclusions: Treatment with dapagliflozin is projected to extend event-free survival by up to 2.0 to 2.5 years among middle-aged and older individuals with HF with mildly reduced or preserved ejection fraction. (DELIVER [Dapagliflozin Evaluation to Improve the Lives of Patients With Preserved Ejection Fraction Heart Failure]; NCT03619213). [ABSTRACT FROM AUTHOR]- Published
- 2022
- Full Text
- View/download PDF
34. Atrial Fibrillation and Dapagliflozin Efficacy in Patients With Preserved or Mildly Reduced Ejection Fraction.
- Author
-
Butt, Jawad H., Kondo, Toru, Jhund, Pardeep S., Comin-Colet, Josep, de Boer, Rudolf A., Desai, Akshai S., Hernandez, Adrian F., Inzucchi, Silvio E., Janssens, Stefan P., Kosiborod, Mikhail N., Lam, Carolyn S.P., Langkilde, Anna Maria, Lindholm, Daniel, Martinez, Felipe, Petersson, Magnus, Shah, Sanjiv J., Thierer, Jorge, Vaduganathan, Muthiah, Verma, Subodh, and Wilderäng, Ulrica
- Subjects
- *
ATRIAL fibrillation , *VENTRICULAR ejection fraction , *DAPAGLIFLOZIN , *LEFT heart ventricle , *EVALUATION research , *RESEARCH funding , *HEART failure , *HEART physiology , *RANDOMIZED controlled trials , *RESEARCH , *STROKE volume (Cardiac output) , *COMPARATIVE studies , *LEFT ventricular dysfunction , *DISEASE complications - Abstract
Background: Atrial fibrillation (AF) is common in heart failure (HF), is associated with worse outcomes compared with sinus rhythm, and may modify the effects of therapy.Objectives: This study examined the effects of dapagliflozin according to the presence or not of AF in the DELIVER (Dapagliflozin Evaluation to Improve the LIVEs of Patients With PReserved Ejection Fraction Heart Failure) trial.Methods: A total of 6,263 patients with HF with New York Heart Association functional class II-IV, left ventricular ejection fraction >40%, evidence of structural heart disease, and elevated N-terminal pro-B-type natriuretic peptide levels were randomized to dapagliflozin or placebo. Clinical outcomes and the effect of dapagliflozin, according to AF status, were examined. The primary outcome was a composite of cardiovascular death or worsening HF.Results: Of the 6,261 patients with data on baseline AF, 43.3% had no AF, 18.0% had paroxysmal AF, and 38.7% had persistent/permanent AF. The risk of the primary endpoint was higher in patients with AF, especially paroxysmal AF, driven by a higher rate of HF hospitalization: no AF, HF hospitalization rate per 100 person-years (4.5 [95% CI: 4.0-5.1]), paroxysmal AF (7.5 [95% CI: 6.4-8.7]), and persistent/permanent AF (6.4 [95% CI: 5.7-7.1]) (P < 0.001). The benefit of dapagliflozin on the primary outcome was consistent across AF types: no AF, HR: 0.89 (95% CI: 0.74-1.08); paroxysmal AF, HR: 0.75 (95% CI: 0.58-0.97); persistent/permanent AF, HR: 0.79 (95% CI: 0.66-0.95) (Pinteraction = 0.49). Consistent effects were observed for HF hospitalization, cardiovascular death, all-cause mortality, and improvement in the KCCQ-TSS.Conclusions: In DELIVER, the beneficial effects of dapagliflozin compared with placebo on clinical events and symptoms were consistent, irrespective of type of AF at baseline. (Dapagliflozin Evaluation to Improve the LIVEs of Patients With PReserved Ejection Fraction Heart Failure. [DELIVER]; NCT03619213). [ABSTRACT FROM AUTHOR]- Published
- 2022
- Full Text
- View/download PDF
35. Metformin therapy in patients with Type 2 diabetes complicated by heart failure.
- Author
-
Inzucchi, Silvio E., Masoudi, Frederick A., and McGuire, Darren K.
- Published
- 2007
- Full Text
- View/download PDF
36. Dapagliflozin in Patients Recently Hospitalized With Heart Failure and Mildly Reduced or Preserved Ejection Fraction.
- Author
-
Cunningham, Jonathan W., Vaduganathan, Muthiah, Claggett, Brian L., Kulac, Ian J., Desai, Akshay S., Jhund, Pardeep S., de Boer, Rudolf A., DeMets, David, Hernandez, Adrian F., Inzucchi, Silvio E., Kosiborod, Mikhail N., Lam, Carolyn S.P., Martinez, Felipe, Shah, Sanjiv J., McGrath, Martina M., O'Meara, Eileen, Wilderäng, Ulrica, Lindholm, Daniel, Petersson, Magnus, and Langkilde, Anna Maria
- Subjects
- *
VENTRICULAR ejection fraction , *HEART failure , *DAPAGLIFLOZIN , *DIABETIC acidosis , *HOSPITAL patients , *LEFT heart ventricle , *BENZENE , *RESEARCH , *GLYCOSIDES , *EVALUATION research , *COMPARATIVE studies , *RANDOMIZED controlled trials , *HOSPITAL care , *HEART physiology , *STROKE volume (Cardiac output) ,CARDIOVASCULAR disease related mortality - Abstract
Background: Patients recently hospitalized for heart failure (HF) are at high risk for rehospitalization and death.Objectives: The purpose of this study was to investigate clinical outcomes and response to dapagliflozin in patients with HF with mildly reduced or preserved left ventricular ejection fraction (LVEF) who were enrolled during or following hospitalization.Methods: The DELIVER (Dapagliflozin Evaluation to Improve the LIVES of Patients With PReserved Ejection Fraction Heart Failure) trial randomized patients with HF and LVEF >40% to dapagliflozin or placebo. DELIVER permitted randomization during or shortly after hospitalization for HF in clinically stable patients off intravenous HF therapies. This prespecified analysis investigated whether recent HF hospitalization modified risk of clinical events or response to dapagliflozin. The primary outcome was worsening HF event or cardiovascular death.Results: Of 6,263 patients in DELIVER, 654 (10.4%) were randomized during HF hospitalization or within 30 days of discharge. Recent HF hospitalization was associated with greater risk of the primary outcome after multivariable adjustment (HR: 1.88; 95% CI: 1.60-2.21; P < 0.001). Dapagliflozin reduced the primary outcome by 22% in recently hospitalized patients (HR: 0.78; 95% CI: 0.60-1.03) and 18% in patients without recent hospitalization (HR: 0.82; 95% CI: 0.72-0.94; Pinteraction = 0.71). Rates of adverse events, including volume depletion, diabetic ketoacidosis, or renal events, were similar with dapagliflozin and placebo in recently hospitalized patients.Conclusions: Dapagliflozin safely reduced risk of worsening HF or cardiovascular death similarly in patients with and without history of recent HF hospitalization. Starting dapagliflozin during or shortly after HF hospitalization in patients with mildly reduced or preserved LVEF appears safe and effective. (Dapagliflozin Evaluation to Improve the LIVEs of Patients With PReserved Ejection Fraction Heart Failure [DELIVER]; NCT03619213). [ABSTRACT FROM AUTHOR]- Published
- 2022
- Full Text
- View/download PDF
37. Electronic Alerts to Improve Heart Failure Therapy in Outpatient Practice: A Cluster Randomized Trial.
- Author
-
Ghazi, Lama, Yamamoto, Yu, Riello, Ralph J., Coronel-Moreno, Claudia, Martin, Melissa, O'Connor, Kyle D., Simonov, Michael, Huang, Joanna, Olufade, Temitope, McDermott, James, Dhar, Ravi, Inzucchi, Silvio E., Velazquez, Eric J., Wilson, F. Perry, Desai, Nihar R., and Ahmad, Tariq
- Subjects
- *
CLUSTER randomized controlled trials , *HEART failure , *MEDICAL prescriptions , *OUTPATIENTS , *MYOCARDIAL depressants , *LEFT heart ventricle , *RESEARCH , *LEFT ventricular dysfunction , *RESEARCH methodology , *EVALUATION research , *TYPE 2 diabetes , *COMPARATIVE studies , *RANDOMIZED controlled trials , *RESEARCH funding , *STROKE volume (Cardiac output) , *HEART physiology , *CARDIOTONIC agents , *ELECTRONICS - Abstract
Background: The use of guideline-directed medical therapy (GDMT) is underprescribed in patients with heart failure with reduced ejection fraction (HFrEF).Objectives: This study sought to examine whether targeted and tailored electronic health record (EHR) alerts recommending GDMT in eligible patients with HFrEF improves GDMT use.Methods: PROMPT-HF (PRagmatic trial Of Messaging to Providers about Treatment of Heart Failure) was a pragmatic, EHR-based, cluster-randomized comparative effectiveness trial. A total of 100 providers caring for patients with HFrEF were randomized to either an alert or usual care. The alert notified providers of individualized GDMT recommendations along with patient characteristics. The primary outcome was an increase in the number of GDMT classes prescribed at 30 days postrandomization. Providers were surveyed on knowledge of guidelines and user experience.Results: The study enrolled 1,310 ambulatory patients with HFrEF from April to October 2021. Median age was 72 years; 31% were female; 18% were Black; and median left ventricular ejection fraction was 32%. At baseline, 84% of participants were receiving β-blockers, 71% received a renin-angiotensin-aldosterone system inhibitor, 29% received a mineralocorticoid receptor antagonist, and 11% received a sodium-glucose cotransporter-2 inhibitor. The primary outcome occurred in 176 of 685 (26%) participants in the alert arm vs 117 of 625 (19%) in the usual care arm, thus increasing GDMT class prescription by >40% after alert exposure (adjusted relative risk: 1.41; 95% CI: 1.03-1.93; P = 0.03). The number of patients needed to alert to result in an increase in addition of GDMT classes was 14. A total of 79% of alerted providers agreed that the alert was effective at enabling improved prescription of medical therapy for HF.Conclusions: A real-time, targeted, and tailored EHR-based alerting system for outpatients with HFrEF led to significantly higher rates of GDMT at 30 days when compared with usual care. This low-cost intervention can be rapidly integrated into clinical care and accelerate adoption of high-value therapies in heart failure. (PRagmatic trial Of Messaging to Providers about Treatment of Heart Failure [PROMPT-HF; NCT04514458]). [ABSTRACT FROM AUTHOR]- Published
- 2022
- Full Text
- View/download PDF
38. RELATIONSHIP BETWEEN INFLAMMATORY BIOMARKERS AND OUTCOMES: AN ANALYSIS FROM DEFINE-HF.
- Author
-
Sherrod, Charles, Sauer, Andrew, Patel, Shachi, Windsor, Sheryl, Nassif, Michael, Husain, Mansoor, Inzucchi, Silvio E., McGuire, Darren K., Pitt, Bertram, Scirica, Benjamin M., Austin, Bethany Anne, Umpierrez, Guillermo, Margulies, Kenneth B., Lanfear, David E., and Kosiborod, Mikhail
- Subjects
- *
BIOMARKERS - Published
- 2024
- Full Text
- View/download PDF
39. THE EFFECT OF DAPAGLIFLOZIN ON DAYS OF FULL HEALTH LOST DUE TO DEATH, HOSPITALIZATION, AND IMPAIRED WELL-BEING IN DAPA-HF.
- Author
-
Kondo, Toru, Mogensen, Ulrik Madvig, Talebi, Atefeh, Gasparyan, Samvel, campbell, ross, Docherty, Kieran F., De Boer, Rudolf A., Inzucchi, Silvio E., K⊘ber, Lars, Kosiborod, Mikhail, Martinez, Felipe A., Sabatine, Marc Steven, Bengtsson, Olof, Sjoestrand, Mikaela, Vaduganathan, Muthiah, Solomon, Scott D., Jhund, Pardeep S., and McMurray, John J.V.
- Subjects
- *
WELL-being , *DAPAGLIFLOZIN , *HOSPITAL care - Published
- 2024
- Full Text
- View/download PDF
40. METABOLIC EFFECTS OF DAPAGLIFLOZIN IN HEART FAILURE ACROSS THE SPECTRUM OF EJECTION FRACTION.
- Author
-
Selvaraj, Senthil, Patel, Shachi, Sauer, Andrew, McGarrah, Robert, Jones, Philip, Kwee, Lydia, Windsor, Sheryl L., Ilkayeva, Olga, Muehlbauer, Michael, Newgard, Christopher B., Borlaug, Barry, Kitzman, Dalane W., Shah, Sanjiv Jayendra, Margulies, Kenneth B., Husain, Mansoor, Inzucchi, Silvio E., McGuire, Darren K., Lanfear, David E., Javaheri, Ali, and Umpierrez, Guillermo
- Subjects
- *
VENTRICULAR ejection fraction , *HEART failure , *DAPAGLIFLOZIN - Published
- 2024
- Full Text
- View/download PDF
41. DAPAGLIFLOZIN IN PATIENTS WITH HEART FAILURE ACROSS A RANGE OF LEFT VENTRICULAR HYPERTROPHY IN THE DELIVER TRIAL.
- Author
-
Vaduganathan, Muthiah, Claggett, Brian, Kulac, Ian, Johansen, Niklas Dyrby, Reza, Nosheen, Jhund, Pardeep S., De Boer, Rudolf A., Hernandez, Adrian F., Inzucchi, Silvio E., Kosiborod, Mikhail, Lam, Carolyn S.P., Martinez, Felipe A., Shah, Sanjiv Jayendra, Desai, Akshay S., Petersson, Magnus, Langkilde, Anna Maria, McMurray, John J.V., and Solomon, Scott D.
- Subjects
- *
LEFT ventricular hypertrophy , *HEART failure patients , *DAPAGLIFLOZIN - Published
- 2024
- Full Text
- View/download PDF
42. Somatic NF1 mutations in pituitary adenomas: Report of two cases.
- Author
-
Hong, Christopher S., Kundishora, Adam J., Elsamadicy, Aladine A., Koo, Andrew B., McGuone, Declan, Inzucchi, Silvio E., Omay, Sacit Bulent, and Erson-Omay, E. Zeynep
- Subjects
- *
GENETIC mutation , *PITUITARY tumors , *SOMATIC mutation , *PITUITARY gland - Published
- 2021
- Full Text
- View/download PDF
43. Shifts in KDIGO CKD risk groups with empagliflozin: Kidney-protection from SGLT2 inhibition across the spectrum of risk.
- Author
-
Weingold, Robert, Zinman, Bernard, Mattheus, Michaela, Ofstad, Anne Pernille, Steubl, Dominik, Wanner, Christoph, and Inzucchi, Silvio E.
- Abstract
T2D is a well-established risk factor for development and progression of CKD. KDIGO recommends categorization of risk by likelihood of progression to ESKD. Compared to placebo, empagliflozin decreases likelihood of worsening (OR 0.70, 95 % CI 0.62–0.78) and increases likelihood of improvement (OR 1.56, 95 % CI 1.30–1.86) in KDIGO risk category. [ABSTRACT FROM AUTHOR]
- Published
- 2023
- Full Text
- View/download PDF
44. THE ASSOCIATION BETWEEN POLYVASCULAR DISEASE AND CARDIOVASCULAR OUTCOMES IN PATIENTS WITH TYPE 2 DIABETES: A SUB-ANALYSIS OF EMPA-REG OUTCOME.
- Author
-
Verma, Subodh, Mazer, C. David, Inzucchi, Silvio E., Wanner, Christoph, Ofstad, Anne Pernille, Johansen, Odd Erik, Zwiener, Isabella, George, Jyothis T., Butler, Javed, and Zinman, Bernard
- Subjects
- *
TYPE 2 diabetes , *CARDIOVASCULAR diseases - Published
- 2020
- Full Text
- View/download PDF
45. DAPAGLIFLOZIN IMPROVES OUTCOMES IRRESPECTIVE OF NT-PROBNP CONCENTRATION IN PATIENTS WITH HFREF: AN ANALYSIS OF THE DAPA-HF TRIAL.
- Author
-
Køber, Lars, Docherty, Kieran, Inzucchi, Silvio E., Jhund, Pardeep, Kosiborod, Mikhail, Langkilde, Anna Maria, Martinez, Felipe, Bengtsson, Olof, Ponikowski, Piotr, Sabatine, Marc, Sjoestrand, Mikaela, Solomon, Scott D., and McMurray, John
- Subjects
- *
DAPAGLIFLOZIN , *HYPOGLYCEMIC agents - Published
- 2020
- Full Text
- View/download PDF
46. CONSISTENT BENEFIT OF DAPAGLIFLOZIN ACCORDING TO BACKGROUND THERAPY IN PATIENTS WITH HFREF: AN ANALYSIS OF THE DAPA-HF TRIAL.
- Author
-
Docherty, Kieran, Jackson, Alice, Inzucchi, Silvio E., Jhund, Pardeep, Kober, Lars, Kosiborod, Mikhail, Langkilde, Anna Maria, Martinez, Felipe, Bengtsson, Olof, Ponikowski, Piotr, Sabatine, Marc, Sjoestrand, Mikaela, Solomon, Scott D., Desai, Akshay S., Diez, Mirta, Howlett, Jonathan, Ljungman, Charlotta E.A., O'Meara, Eileen, Petrie, Mark, and Schou, Morten
- Subjects
- *
DAPAGLIFLOZIN - Published
- 2020
- Full Text
- View/download PDF
47. THE EFFECT OF DAPAGLIFLOZIN ON INSULIN INITIATION OR INTENSIFICATION IN PATIENTS IN HEART FAILURE AND DIABETES: A POOLED ANALYSIS OF DAPA-HF AND DELIVER.
- Author
-
McMurray, John J.V., Docherty, Kieran F., Jhund, Pardeep, Claggett, Brian, De Boer, Rudolf A., Hernandez, Adrian F., Inzucchi, Silvio E., Kober, Lars, Kosiborod, Mikhail, Lam, Carolyn S.P., Martinez, Felipe A., Ponikowski, Piotr, Sabatine, Marc Steven, Shah, Sanjiv Jayendra, Langkilde, Anna Maria, Petersson, Magnus, and Solomon, Scott D.
- Subjects
- *
HEART failure patients , *INSULIN , *DAPAGLIFLOZIN , *DIABETES - Published
- 2023
- Full Text
- View/download PDF
48. WORSE VASCULAR RISK FACTOR CONTROL IN PATIENTS WITH STROKE COMPARED TO PATIENTS WITH MYOCARDIAL INFARCTION.
- Author
-
Leasure, Audrey, Acosta, Julian, Schwartz, Anna, Forman, Rachel, Sharma, Richa, de Havenon, Adam, Falcone, Guido J., Inzucchi, Silvio E., Kernan, Walter, and Sheth, Kevin N.
- Subjects
- *
DISEASE risk factors , *STROKE patients , *STROKE , *MYOCARDIAL infarction - Published
- 2022
- Full Text
- View/download PDF
49. U.S. PATTERNS OF DRUG UTILIZATION AND PRESCRIPTION FILLS FOR PROVEN CARDIOPROTECTIVE ANTI-HYPERGLYCEMIC AGENTS.
- Author
-
Nargesi, Arash Aghajani, Clark, Callahan, Liu, Mengni, Chen, Lian, Reddy, Abraham, Amodeo, Samuel, Oikonomou, Evangelos K., Suchard, Marc, Lipska, Kasia, McGuire, Darren K., Lin, Zhenqiu, Inzucchi, Silvio E., Krumholz, Harlan M., and Khera, Rohan
- Subjects
- *
HYPOGLYCEMIC agents , *DRUG utilization , *CARDIOTONIC agents , *DRUGS - Published
- 2022
- Full Text
- View/download PDF
50. DCRM Multispecialty Practice Recommendations for the management of diabetes, cardiorenal, and metabolic diseases.
- Author
-
Handelsman, Yehuda, Anderson, John E., Bakris, George L., Ballantyne, Christie M., Beckman, Joshua A., Bhatt, Deepak L., Bloomgarden, Zachary T., Bozkurt, Biykem, Budoff, Matthew J., Butler, Javed, Dagogo-Jack, Samuel, de Boer, Ian H., DeFronzo, Ralph A., Eckel, Robert H., Einhorn, Daniel, Fonseca, Vivian A., Green, Jennifer B., Grunberger, George, Guerin, Chris, and Inzucchi, Silvio E.
- Abstract
Type 2 diabetes (T2D), chronic kidney disease (CKD), atherosclerotic cardiovascular disease (ASCVD), and heart failure (HF)-along with their associated risk factors-have overlapping etiologies, and two or more of these conditions frequently occur in the same patient. Many recent cardiovascular outcome trials (CVOTs) have demonstrated the benefits of agents originally developed to control T2D, ASCVD, or CKD risk factors, and these agents have transcended their primary indications to confer benefits across a range of conditions. This evolution in CVOT evidence calls for practice recommendations that are not constrained by a single discipline to help clinicians manage patients with complex conditions involving diabetes, cardiorenal, and/or metabolic (DCRM) diseases. The ultimate goal for these recommendations is to be comprehensive yet succinct and easy to follow by the nonexpert-whether a specialist or a primary care clinician. To meet this need, we formed a volunteer task force comprising leading cardiologists, nephrologists, endocrinologists, and primary care physicians to develop the DCRM Practice Recommendations, a multispecialty consensus on the comprehensive management of the patient with complicated metabolic disease. The task force recommendations are based on strong evidence and incorporate practical guidance that is clinically relevant and simple to implement, with the aim of improving outcomes in patients with DCRM. The recommendations are presented as 18 separate graphics covering lifestyle therapy, patient self-management education, technology for DCRM management, prediabetes, cognitive dysfunction, vaccinations, clinical tests, lipids, hypertension, anticoagulation and antiplatelet therapy, antihyperglycemic therapy, hypoglycemia, nonalcoholic fatty liver disease (NAFLD) and nonalcoholic steatohepatitis (NASH), ASCVD, HF, CKD, and comorbid HF and CKD, as well as a graphical summary of medications used for DCRM. [ABSTRACT FROM AUTHOR]
- Published
- 2022
- Full Text
- View/download PDF
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.